Influence of interleukin-4 gene polymorphisms and interleukin-4 serum level on susceptibility and severity of rheumatoid arthritis in Egyptian population

被引:52
作者
Hussein, Yousri M. [1 ,2 ]
El-Shal, Amal S. [1 ]
Rezk, Noha A. [1 ]
Galil, Sahar M. Abdel [3 ]
Alzahrani, Saad S. [4 ]
机构
[1] Zagazig Univ, Fac Med, Dept Med Biochem, Zagazig, Egypt
[2] El Taif Univ, Fac Appl Med Sci, Med Labs Dept, At Taif, Saudi Arabia
[3] Zagazig Univ, Fac Med, Rheumatol & Rehabil Dept, Zagazig, Egypt
[4] El Taief Univ, Fac Appl Med Sci, Dept Family Med, At Taif, Saudi Arabia
关键词
Rheumatoid arthritis; IL-4; VNTR; IL-4-590; promoter; Polymorphism; Egyptian population; ASSOCIATION; PROGRESSION; ACTIVATION; ASTHMA; IL-10;
D O I
10.1016/j.cyto.2013.01.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Background: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease in which interleukin-4 (IL-4) plays an important role. This study aimed to investigate the influence of IL-4 variable number of tandem repeats (VNTRs) and IL-4-590 promoter polymorphisms on RA susceptibility, activity and severity in Egyptian population. Materials and methods: One hundred and seventy-two RA patients and 172 controls were enrolled in this study. IL-4 VNTR and IL-4-590 promoter polymorphisms were genotyped using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Serum IL-4 and anti-cyclic citrullinated peptides (anti-CCPs) antibody concentrations were measured by enzyme linked immunosorbent assay (ELISA). Results: Subjects with IL-4-590 TT genotype were significantly more likely to develop RA. IL-4 VNTR 1/1 genotype, IL-4-590 IT and CT genotypes were significantly more associated with erosive RA and positive anti-CCP antibody. RA severity parameters were significantly increased, while, IL-4 level was significantly decreased in RA patients with IL-4 VNTR 1/1 and IL-4-590 TT genotypes. Only patients with IL-4-590 TT genotype showed a significant increase of all RA activity parameters. Conclusion: IL-4 VNTR and IL-4-590 promoter polymorphisms may be helpful for assessing RA severity in Egyptian population. Moreover, IL-4-590 promoter polymorphism may be associated with increased risk and activity of RA. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:849 / 855
页数:7
相关论文
共 44 条
[1]
CYTOKINES AND CYTOKINE INHIBITORS OR ANTAGONISTS IN RHEUMATOID-ARTHRITIS [J].
AREND, WP ;
DAYER, JM .
ARTHRITIS AND RHEUMATISM, 1990, 33 (03) :305-315
[2]
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review [J].
Avouac, J. ;
Gossec, L. ;
Dougados, M. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) :845-851
[3]
Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms [J].
Balsa, Alejandro ;
del Amo, Jokin ;
Blanco, Francisco ;
Caliz, Rafael ;
Silva, Lucia ;
Sanmarti, Raimon ;
Martinez, Francisco G. ;
Tejedor, Diego ;
Artieda, Marta ;
Pascual-Salcedo, Dora ;
Oreiro, Natividad ;
Collado, Maria D. ;
Andreu, Jose L. ;
Graell, Eduard ;
Simon, Laureano ;
Martinez, Antonio ;
Mulero, Juan .
RHEUMATOLOGY, 2010, 49 (03) :458-466
[4]
Benucci Maurizio, 2006, Recenti Progressi in Medicina, V97, P134
[5]
IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction [J].
Buchs, N ;
Silvestri, T ;
di Giovine, FS ;
Chabaud, M ;
Vannier, E ;
Duff, GW ;
Miossec, P .
RHEUMATOLOGY, 2000, 39 (10) :1126-1131
[6]
Cantagrel A, 1999, ARTHRITIS RHEUM, V42, P1093, DOI 10.1002/1529-0131(199906)42:6<1093::AID-ANR5>3.0.CO
[7]
2-P
[8]
Castro A, 1999, J IMMUNOL, V162, P1261
[9]
Epstein-Barr virus and rheumatoid arthritis: is there a link? [J].
Costenbader, KH ;
Karlson, EW .
ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)
[10]
Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation [J].
Dimitrova, P ;
Skapenko, A ;
Herrmann, ML ;
Schleyerbach, R ;
Kalden, JR ;
Schulze-Koops, H .
JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :3392-3399